Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient

Abstract

The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.

Description

TECHNICAL FIELD[0001]The present invention relates to an agent for treating inflammatory diseases such as sepsis and hepatitis, more particularly, to a therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient.BACKGROUND ART[0002]At present, there has not yet been explored a chemotherapeutic agent that exerts a satisfactory result for inflammatory diseases such as sepsis and hepatitis, and there have been only applied steroids, anti-inframmatories, platelet aggregation inhibitors, vasodilators, antibiotics, etc., as supportive measures to the above diseases. Since these inflammatory diseases exhibit serious symptoms in many cases, there has been desired an exploitation of therapeutically effective agents with no or lesser side-effects but with safeness.[0003]It is known that many cytokines are involved in various inflammatory diseases in living bodies. Examples of such inflammatory cytokines include a number of tumor necrosis factor (TNF-α...

AI Technical Summary

Benefits of technology

[0009]Further, the present inventors found that a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient has an action of inhibiting the production of inflammatory cytokines such as TNF-α, IL-1, IL-4, IL-5, IL-6, IL-8 and IL-12, which have been considered as effector molecules for the onset or the exacerbation of inflammatory diseases; and that it has an action of enhancing the production of IL-10 as an anti-inflammatory cytokine that is recognized to contribute to the inhibition of inflammatory diseases. They also found that it can be used for the manufacture of a TNF-α production inhibitor, IL-1 production inhibitor, IL-4 production inhibitor, IL-5 production inhibitor, IL-6 production inhibitor, IL-8 production inhibitor, IL-12 production inhibitor, or IL-10 production enhancer for use in the treatment of inflammatory diseases. Thus, they accomplished the present invention.

[0013]The therapeutic agent, containing adenosine N1-oxide or a derivative thereof as an effective ingredient, effectively prevents or treats inflammatory diseases such as sepsis, rheumatoid arthritis, ARDS, hepatitis, and inflammatory bowel disease. In addition, the therapeutic agent of the present invention effectively inhibits the production of inflammatory cytokines such as TNF-α, IL-1, IL-4, IL-5, IL-6, IL-8, and IL-12. Further, the therapeutic agent effectively enhances the production of IL-10.

Problems solved by technology

At present, there has not yet been explored a chemotherapeutic agent that exerts a satisfactory result for inflammatory diseases such as sepsis and hepatitis, and there have been only applied steroids, anti-inframmatories, platelet aggregation inhibitors, vasodilators, antibiotics, etc., as supportive measures to the above diseases.

WO03 / 007974) have been tried to apply for the treatment of such inflammatory diseases; however, no satisfactory effect has not yet been attained thereby, and in some cases, a relatively long term administration thereof may cause side effects as a problem.

There exists a finding that adenosine has an anti-inflammatory action and an ischemic injury inhibitory action, however, it has relatively strong systemic side-effects.

Because of this, clinical application thereof is limited.